MX345169B - Agente terapeutico para trastornos de la motilidad. - Google Patents

Agente terapeutico para trastornos de la motilidad.

Info

Publication number
MX345169B
MX345169B MX2011011269A MX2011011269A MX345169B MX 345169 B MX345169 B MX 345169B MX 2011011269 A MX2011011269 A MX 2011011269A MX 2011011269 A MX2011011269 A MX 2011011269A MX 345169 B MX345169 B MX 345169B
Authority
MX
Mexico
Prior art keywords
therapeutic
prophylactic agent
motor disorder
therapeutic agent
motor disorders
Prior art date
Application number
MX2011011269A
Other languages
English (en)
Other versions
MX2011011269A (es
Inventor
Uesaka Noriaki
Kanda Tomoyuki
Sawada Takashi
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX345169(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of MX2011011269A publication Critical patent/MX2011011269A/es
Publication of MX345169B publication Critical patent/MX345169B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención proporciona un agente para el tratamiento y/o profilaxis de un trastorno de movimiento, el agente para el tratamiento y/o profilaxis en donde el trastorno de movimiento es un síndrome extrapiramidal, el agente para el tratamiento y/o profilaxis en donde el trastorno de movimiento es bradiquinesia, alteración en el modo de andar, distonía, disquinesia o disquinesia tardía, el agente para el tratamiento y/o profilaxis en donde el trastorno de movimiento es un efecto colateral de la terapia con L-DOPA y/o un agonista de dopamina y similares cada uno contiene un derivado de tiazol representado por la fórmula (I) en donde R1 representa arilo y similares y R2 representa piridilo o similares o una sal farmacéuticamente aceptable del mismo como ingrediente activo.(ver fórmula (I)).
MX2011011269A 2009-04-28 2010-04-28 Agente terapeutico para trastornos de la motilidad. MX345169B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009109434 2009-04-28
PCT/JP2010/057563 WO2010126082A1 (ja) 2009-04-28 2010-04-28 運動障害治療剤

Publications (2)

Publication Number Publication Date
MX2011011269A MX2011011269A (es) 2011-11-18
MX345169B true MX345169B (es) 2017-01-19

Family

ID=43032226

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011269A MX345169B (es) 2009-04-28 2010-04-28 Agente terapeutico para trastornos de la motilidad.

Country Status (25)

Country Link
US (4) US20120101101A1 (es)
EP (2) EP3378860A1 (es)
JP (1) JP5687617B2 (es)
KR (2) KR20160087926A (es)
CN (3) CN104557904A (es)
AU (1) AU2010242375B2 (es)
BR (1) BRPI1011768A8 (es)
CA (1) CA2760048C (es)
CL (1) CL2011002650A1 (es)
EA (1) EA027308B1 (es)
ES (1) ES2678119T3 (es)
HK (1) HK1169115A1 (es)
HU (1) HUE038319T2 (es)
IL (1) IL215963A (es)
MX (1) MX345169B (es)
MY (1) MY166649A (es)
NZ (1) NZ596362A (es)
PL (1) PL2433938T3 (es)
PT (1) PT2433938T (es)
SG (2) SG10201401698QA (es)
TR (1) TR201809003T4 (es)
TW (1) TWI548411B (es)
UA (1) UA112957C2 (es)
WO (1) WO2010126082A1 (es)
ZA (1) ZA201108665B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3002283T1 (en) * 2003-12-26 2018-06-29 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
CA3103771A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt
US11034658B2 (en) 2018-06-18 2021-06-15 Janssen Pharmaceutica Nv Pyridinyl pyrazoles as modulators of RORγT
CA3103929A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
JP2021527660A (ja) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160899B2 (en) * 2001-04-09 2007-01-09 Neurosearch A/S Adenosine A2A receptor antangonists combined with neurotrophic activity compounds in the treatment of Parkinson's disease
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
CA2473864C (en) * 2002-01-28 2013-06-11 Kyowa Hakko Kogyo Co., Ltd. Composition for use in treating patients suffering from movement disorder
SI3002283T1 (en) * 2003-12-26 2018-06-29 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
CA2581105A1 (en) * 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
US20090030017A1 (en) * 2005-04-08 2009-01-29 Eisai R & D Management Co., Ltd Therapeutic agent for dyskinesia
JPWO2006132275A1 (ja) * 2005-06-07 2009-01-08 協和醗酵工業株式会社 運動障害の予防および／または治療剤
JPWO2006137527A1 (ja) 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
PT1921077T (pt) * 2005-08-02 2017-10-26 Kyowa Hakko Kirin Co Ltd Agente para tratar e/ou prevenir distúrbio do sono
US20090005568A1 (en) 2005-08-18 2009-01-01 Pharmacopeia Drug Discovery, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
CA2655987A1 (en) 2006-06-26 2008-01-03 Schering Corporation Adenosine a2a receptor antagonists
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
ES2658892T3 (es) 2008-07-23 2018-03-12 Kyowa Hakko Kirin Co., Ltd. Agente terapéutico para la migraña

Also Published As

Publication number Publication date
SG175368A1 (en) 2011-11-28
ES2678119T3 (es) 2018-08-09
EP2433938A1 (en) 2012-03-28
JP5687617B2 (ja) 2015-03-18
PL2433938T3 (pl) 2018-09-28
CN104606190B (zh) 2018-01-19
WO2010126082A1 (ja) 2010-11-04
CN102414209A (zh) 2012-04-11
CL2011002650A1 (es) 2012-06-15
EA027308B1 (ru) 2017-07-31
CN104606190A (zh) 2015-05-13
BRPI1011768A2 (pt) 2016-03-29
BRPI1011768A8 (pt) 2018-01-02
HK1169115A1 (en) 2013-01-18
KR20120023019A (ko) 2012-03-12
IL215963A (en) 2016-06-30
TR201809003T4 (tr) 2018-07-23
CN102414209B (zh) 2015-01-28
US20190359631A1 (en) 2019-11-28
MY166649A (en) 2018-07-18
TWI548411B (zh) 2016-09-11
CA2760048A1 (en) 2010-11-04
US20170275296A1 (en) 2017-09-28
EP3378860A1 (en) 2018-09-26
HUE038319T2 (hu) 2018-10-29
EP2433938B1 (en) 2018-04-18
AU2010242375B2 (en) 2015-11-05
NZ596362A (en) 2014-03-28
IL215963A0 (en) 2012-01-31
KR101692091B1 (ko) 2017-01-02
US10407440B2 (en) 2019-09-10
CA2760048C (en) 2016-04-26
CN104557904A (zh) 2015-04-29
MX2011011269A (es) 2011-11-18
EP2433938A4 (en) 2013-03-27
ZA201108665B (en) 2018-11-28
SG10201401698QA (en) 2014-06-27
UA112957C2 (uk) 2016-11-25
US20150225417A1 (en) 2015-08-13
EA201171305A1 (ru) 2012-05-30
US20120101101A1 (en) 2012-04-26
TW201103541A (en) 2011-02-01
PT2433938T (pt) 2018-07-13
KR20160087926A (ko) 2016-07-22
AU2010242375A1 (en) 2011-12-08
US9714257B2 (en) 2017-07-25
JPWO2010126082A1 (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
MX345169B (es) Agente terapeutico para trastornos de la motilidad.
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY
PH12016502246A1 (en) Carboxamide derivatives
TN2016000491A1 (en) Carboxamide derivatives.
SA519402090B1 (ar) مثبطات انتقائية لـ hdac6، وطريقة تحضيرها، واستخدامها
TN2014000060A1 (en) Benzothiazolone compound
CY1119483T1 (el) Θεραπευτικος παραγων για τις αγχωδεις διαταραχες
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
PH12015501056A1 (en) 2-pyridone compound
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.
MX355654B (es) Derivado de paroxetina.
WO2012169863A3 (en) 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof
PH12016502247A1 (en) Carboxamide derivatives

Legal Events

Date Code Title Description
FG Grant or registration